Guidance for palivizumab prophylaxis and implications for compliance

Pediatr Pulmonol. 2021 Dec;56(12):3575-3576. doi: 10.1002/ppul.25634. Epub 2021 Sep 21.

Authors

Mitchell Goldstein¹, Benjamin Harding¹, Elba Fayard¹

Affiliation

¹ Division of Neonatology, Loma Linda University Children's Hospital, Loma Linda, California, USA.

PMID: 34547834
DOI: 10.1002/ppul.25634

No abstract available

Keywords: AAP; NPA; RSV; palivizumab; prophylaxis.

Publication types

Editorial

MeSH terms

Antiviral Agents / therapeutic use
Hospitalization
Humans
Infant
Palivizumab / therapeutic use
Respiratory Syncytial Virus Infections* / drug therapy
Respiratory Syncytial Virus Infections* / prevention & control

Substances

Antiviral Agents
Palivizumab